Eiji Nishio
Overview
Explore the profile of Eiji Nishio including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
123
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hayashi T, Kumamoto K, Kobayashi T, Hou X, Nagao S, Harada N, et al.
FEBS J
. 2025 Feb;
PMID: 39967403
Estrogen is synthesized throughout various tissues in the body, and its production is regulated by the rate-limiting enzyme aromatase (encoded by the Cyp19a1 gene). Notably, aromatase is also expressed in...
2.
Aida N, Nishio E, Sekiya T, Aida N, Ito T, Kenmochi T, et al.
Fujita Med J
. 2025 Feb;
11(1):52-53.
PMID: 39896225
Although organ transplantation is becoming general practice, little is known about the safety of delivery. This is the first known case that describes injury to the kidney by the uterine...
3.
Takada K, Nishio E, Kotani K, Kobayashi A, Owaki A, Noda Y, et al.
Fujita Med J
. 2025 Feb;
11(1):48-51.
PMID: 39896222
We report a case where a spontaneous pregnancy and delivery of a live baby were achieved after laparoscopic repair combined with hysteroscopy of the cesarean section scar secondary to treatment...
4.
Nishibe-Toyosato S, Ando Y, Torii Y, Ichikawa R, Owaki A, Miyamura H, et al.
In Vivo
. 2024 Aug;
38(5):2374-2382.
PMID: 39187311
Background/aim: The frequency rate of injection site reactions (ISR) due to fosaprepitant meglumine (Fos APR) has been shown to vary depending on the types of combined anticancer drug. This study...
5.
Kawasaki R, Kukimoto I, Tsukamoto T, Nishio E, Iwata A, Fujii T
Cancer Sci
. 2024 Aug;
115(11):3672-3681.
PMID: 39171738
Approximately 660,000 women are diagnosed with cervical cancer annually. Current screening options such as cytology or human papillomavirus testing have limitations, creating a need to identify more effective ancillary biomarkers...
6.
Fujii T, Nishio E, Tsukamoto T, Kukimoto I, Iwata A
Cancer Sci
. 2024 May;
115(8):2795-2807.
PMID: 38749770
Currently, human papillomavirus tests and cytology are used to screen for cervical cancer. However, more accurate ancillary screening tests are needed. MicroRNAs (miRNAs) and cytokines are promising biomarkers that are...
7.
Nishio E, Ishitani K, Arimoto T, Igarashi T, Ishikawa T, Iwase A, et al.
J Obstet Gynaecol Res
. 2024 Apr;
50(7):1073-1094.
PMID: 38627197
Twelve years after the first edition of The Guideline for Gynecological Practice, which was jointly edited by The Japan Society of Obstetrics and Gynecology and The Japan Association of Obstetricians...
8.
Miyamura H, Takada K, Ohwaki A, Kobayashi A, Ito M, Nomura H, et al.
Asian J Endosc Surg
. 2024 Mar;
17(2):e13298.
PMID: 38479382
Introduction: The da Vinci SP surgical system is a surgical platform capable of implementing robotic-assisted surgery through a single port and was first introduced in Japan at our hospital. In...
9.
Nishio E, Iwata A, Kawasaki R, Iwao K, Nishizawa H, Fujii T
Reprod Med Biol
. 2024 Mar;
23(1):e12568.
PMID: 38476960
Purpose: In the context of in vitro fertilization-embryo transfer (IVF-ET), factors other than egg quality may be key determinants of treatment success, in particular, maternal factors related to uterine endometrial...
10.
Nishio E, Sakabe Y, Fujii T
Fujita Med J
. 2023 May;
9(2):160-162.
PMID: 37234393
Multilocular cystic leiomyomas rarely develop following myomectomy. To the best of our knowledge, there are no published reports on recurrent multilocular cystic leiomyoma following myomectomy. We here present such a...